2Seventy Bio IncNASDAQ:TSVT
- LAST PRICE4.0300
- TODAY'S CHANGE (%)0.0200 (0.4988%)
- Bid / Lots3.8000/ 101
- Ask / Lots4.2000/ 15
- Open / Previous Close3.9600 / 4.0100
- Day Range
- 52 Week Range
- Volume336,357
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TSVT |
|---|---|---|
| 09:32 ET | 4706 | 3.9329 |
| 09:34 ET | 1853 | 3.98 |
| 09:36 ET | 200 | 4 |
| 09:38 ET | 3499 | 4.04 |
| 09:39 ET | 18649 | 4.025 |
| 09:41 ET | 100 | 4.025 |
| 09:43 ET | 600 | 4.05 |
| 09:48 ET | 3030 | 4.04 |
| 09:50 ET | 200 | 4.03 |
| 09:52 ET | 2563 | 4.0065 |
| 09:54 ET | 1100 | 3.98 |
| 09:56 ET | 743 | 3.95 |
| 09:57 ET | 2500 | 3.96 |
| 09:59 ET | 600 | 3.95 |
| 10:01 ET | 300 | 3.95 |
| 10:03 ET | 700 | 3.955 |
| 10:06 ET | 400 | 3.94 |
| 10:08 ET | 200 | 3.95 |
| 10:10 ET | 100 | 3.95 |
| 10:12 ET | 400 | 3.94 |
| 10:14 ET | 12160 | 3.98 |
| 10:17 ET | 100 | 3.98 |
| 10:21 ET | 1000 | 3.97 |
| 10:24 ET | 100 | 3.97 |
| 10:26 ET | 600 | 3.97 |
| 10:28 ET | 1687 | 3.96 |
| 10:30 ET | 773 | 3.96 |
| 10:32 ET | 682 | 3.95 |
| 10:33 ET | 535 | 3.96 |
| 10:35 ET | 100 | 3.96 |
| 10:37 ET | 966 | 3.9501 |
| 10:42 ET | 1338 | 3.97 |
| 10:44 ET | 200 | 3.97 |
| 10:48 ET | 492 | 3.98 |
| 10:50 ET | 200 | 3.98 |
| 10:51 ET | 200 | 3.9899 |
| 10:55 ET | 871 | 4.01 |
| 10:57 ET | 100 | 4.01 |
| 11:00 ET | 2900 | 4 |
| 11:02 ET | 600 | 3.975 |
| 11:06 ET | 619 | 3.97 |
| 11:08 ET | 100 | 3.99 |
| 11:09 ET | 300 | 3.98 |
| 11:22 ET | 100 | 3.99 |
| 11:24 ET | 300 | 3.98 |
| 11:26 ET | 490 | 3.975 |
| 11:27 ET | 400 | 3.98 |
| 11:29 ET | 200 | 3.9899 |
| 11:33 ET | 600 | 3.98 |
| 11:36 ET | 1000 | 3.971 |
| 11:40 ET | 1200 | 3.9899 |
| 11:42 ET | 600 | 3.97 |
| 11:44 ET | 748 | 3.99 |
| 11:45 ET | 900 | 3.99 |
| 11:47 ET | 200 | 3.99 |
| 11:49 ET | 300 | 3.99 |
| 11:51 ET | 200 | 3.99 |
| 11:54 ET | 200 | 3.99 |
| 11:56 ET | 952 | 3.98 |
| 12:00 ET | 400 | 3.98 |
| 12:02 ET | 100 | 3.97 |
| 12:03 ET | 500 | 3.96 |
| 12:09 ET | 2872 | 3.93 |
| 12:12 ET | 600 | 3.93 |
| 12:14 ET | 200 | 3.94 |
| 12:16 ET | 100 | 3.93 |
| 12:20 ET | 100 | 3.93 |
| 12:23 ET | 100 | 3.93 |
| 12:27 ET | 1400 | 3.94 |
| 12:32 ET | 315 | 3.92 |
| 12:34 ET | 600 | 3.91 |
| 12:36 ET | 2000 | 3.9001 |
| 12:38 ET | 636 | 3.91 |
| 12:39 ET | 836 | 3.9 |
| 12:41 ET | 1502 | 3.91 |
| 12:45 ET | 400 | 3.9 |
| 12:48 ET | 300 | 3.89 |
| 12:50 ET | 252 | 3.89 |
| 12:52 ET | 400 | 3.88 |
| 12:54 ET | 400 | 3.88 |
| 12:56 ET | 200 | 3.89 |
| 12:57 ET | 1700 | 3.8977 |
| 12:59 ET | 100 | 3.89 |
| 01:01 ET | 1403 | 3.895 |
| 01:03 ET | 400 | 3.895 |
| 01:06 ET | 200 | 3.89 |
| 01:10 ET | 100 | 3.89 |
| 01:19 ET | 775 | 3.9 |
| 01:24 ET | 100 | 3.89 |
| 01:26 ET | 1000 | 3.8929 |
| 01:32 ET | 300 | 3.885 |
| 01:35 ET | 1273 | 3.89 |
| 01:39 ET | 200 | 3.89 |
| 01:46 ET | 1106 | 3.91 |
| 01:48 ET | 767 | 3.92 |
| 01:50 ET | 100 | 3.91 |
| 01:57 ET | 100 | 3.91 |
| 02:02 ET | 100 | 3.915 |
| 02:04 ET | 500 | 3.91 |
| 02:09 ET | 100 | 3.91 |
| 02:13 ET | 3400 | 3.905 |
| 02:20 ET | 1146 | 3.905 |
| 02:22 ET | 1605 | 3.91 |
| 02:24 ET | 100 | 3.9 |
| 02:26 ET | 322 | 3.91 |
| 02:29 ET | 2124 | 3.92 |
| 02:36 ET | 100 | 3.92 |
| 02:40 ET | 100 | 3.92 |
| 02:44 ET | 100 | 3.925 |
| 02:45 ET | 1200 | 3.925 |
| 02:49 ET | 694 | 3.93 |
| 02:51 ET | 100 | 3.93 |
| 02:54 ET | 1206 | 3.935 |
| 02:56 ET | 2360 | 3.931 |
| 02:58 ET | 700 | 3.931 |
| 03:00 ET | 720 | 3.92 |
| 03:03 ET | 500 | 3.925 |
| 03:05 ET | 7005 | 3.9 |
| 03:07 ET | 977 | 3.905 |
| 03:09 ET | 2473 | 3.92 |
| 03:12 ET | 3429 | 3.94 |
| 03:18 ET | 610 | 3.95 |
| 03:20 ET | 11960 | 3.97 |
| 03:21 ET | 1029 | 3.98 |
| 03:23 ET | 1594 | 3.99 |
| 03:25 ET | 400 | 3.99 |
| 03:27 ET | 260 | 3.99 |
| 03:30 ET | 400 | 3.99 |
| 03:32 ET | 2101 | 4 |
| 03:36 ET | 300 | 4 |
| 03:38 ET | 4198 | 4.01 |
| 03:39 ET | 3715 | 4.01 |
| 03:41 ET | 500 | 4 |
| 03:43 ET | 2036 | 4.005 |
| 03:45 ET | 3340 | 4.01 |
| 03:48 ET | 769 | 4.0045 |
| 03:50 ET | 300 | 4.01 |
| 03:52 ET | 3016 | 4.02 |
| 03:54 ET | 2114 | 4.02 |
| 03:56 ET | 15425 | 4.02 |
| 03:57 ET | 6129 | 4.02 |
| 03:59 ET | 16590 | 4.03 |
Jun 27, 2024
DJ 2seventy bio Price Target Maintained With a $5.00/Share by Wedbush, from 9:50AM ET on Thursday Jun 27, 2024 by Dow Jones
9:50AM ET on Thursday Jun 27, 2024 by Dow Jones
Jun 26, 2024
DJ 2seventy Bio Sells Gene Editing Therapy To Novo Nordisk for Up To $40 Million, from 4:40PM ET on Wednesday Jun 26, 2024 by Dow Jones
4:40PM ET on Wednesday Jun 26, 2024 by Dow Jones*DJ 2seventy Bio: Divestiture Will Include Transfer of 2seventy Bio's megaTAL Technology and License to Underlying Intellectual Property >TSVT, from 4:14PM ET on Wednesday Jun 26, 2024 by Dow Jones
4:14PM ET on Wednesday Jun 26, 2024 by Dow Jones2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million, from 4:11PM ET on Wednesday Jun 26, 2024 by Dow Jones
4:11PM ET on Wednesday Jun 26, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
2Seventy Bio Inc | 207.2M | -0.9x | --- |
CytomX Therapeutics Inc | 100.5M | 6.5x | --- |
Chromadex Corp | 189.6M | -53.4x | --- |
Spero Therapeutics Inc | 70.7M | 3.1x | --- |
Rigel Pharmaceuticals Inc | 136.6M | -6.9x | --- |
G1 Therapeutics Inc | 131.2M | -4.1x | --- |
Company Information
2seventy bio, Inc. is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The Company is focused on the commercialization and development of Abecma (idecabtagene vicleucel). Abecma is its B cell maturation antigen (BCMA)-targeted CAR T cell therapy for multiple myeloma, in collaboration with their partner Bristol Myers Squibb (BMS). ABECMA is a BCMA-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Abecma uses a lentiviral vector (LVV), to deliver a chimeric antigen receptor (CAR), with the potential to program a patient’s own T cells to recognize the plasma cell specific BCMA, protein on the cell surface.
Contact Information
- Headquarters
- 60 Binney StreetCAMBRIDGE, MA, United States 02210
- Phone
- 339-499-9300
- Fax
- 302-636-5454
Executives
- Chairman of the Board
- Nick Leschly
- President, Chief Executive Officer, Director
- William Baird
- Chief Financial Officer
- Victoria Eatwell
- Senior Vice President - Quality & Head of Operations
- Jessica Snow
- Lead Independent Director
- Denice Torres
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $207.2M |
|---|---|
Revenue (TTM) | $71.2M |
Shares Outstanding | 51.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-4.34 |
Book Value | $5.04 |
P/E Ratio | -0.9x |
Price/Sales (TTM) | 2.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -332.93% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
